| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 674 | 2015 |
| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 535 | 2019 |
| Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement IAM Macphee, S Fredericks, T Tai, P Syrris, ND Carter, A Johnston, ... Transplantation 74 (11), 1486-1489, 2002 | 424 | 2002 |
| Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. IA MacPhee, FA Antoni, DW Mason The Journal of experimental medicine 169 (2), 431-445, 1989 | 385 | 1989 |
| The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation IAM MacPhee, S Fredericks, T Tai, P Syrris, ND Carter, A Johnston, ... American Journal of Transplantation 4 (6), 914-919, 2004 | 317 | 2004 |
| Tacrolimus pharmacogenetics: the CYP3A5* 1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians IAM MacPhee, S Fredericks, M Mohamed, M Moreton, ND Carter, ... Transplantation 79 (4), 499-502, 2005 | 264 | 2005 |
| The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. D Mason, I MacPhee, F Antoni Immunology 70 (1), 1, 1990 | 238 | 1990 |
| Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment? I Rebollo-Mesa, E Nova-Lamperti, P Mobillo, M Runglall, S Christakoudi, ... American Journal of Transplantation 16 (12), 3443-3457, 2016 | 112 | 2016 |
| A renal registry for Africa: first steps MR Davids, JB Eastwood, NH Selwood, FA Arogundade, G Ashuntantang, ... Clinical kidney journal 9 (1), 162-167, 2016 | 110 | 2016 |
| European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. T van Gelder Transplant International 24 (12), 2011 | 110 | 2011 |
| Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? K Lane, JJ Dixon, IAM MacPhee, BJ Philips Nephrology dialysis transplantation 28 (7), 1634-1647, 2013 | 100 | 2013 |
| Isolation of encephalitogenic CD4+ T cell clones in the rat: Cloning methodology and interferon-γ secretion JD Sedgwick, IAM MacPhee, M Puklavec Journal of immunological methods 121 (2), 185-196, 1989 | 91 | 1989 |
| Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements S Fredericks, M Moreton, S Reboux, ND Carter, L Goldberg, DW Holt, ... Transplantation 82 (5), 705-708, 2006 | 83 | 2006 |
| LONG-TERM OUTCOME OF A PROSPECTIVE RANDOMIZED TRIAL OF CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE TREATMENT ONE YEAR AFTER RENAL TRANSPLANTATION1 IAM MacPhee, JA Bradley, JD Briggs, BJR Junor, SG MacPherson, ... Transplantation 66 (9), 1186-1192, 1998 | 83 | 1998 |
| Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients T Heller, T Van Gelder, K Budde, JW De Fijter, D Kuypers, W Arns, ... American journal of transplantation 7 (7), 1822-1831, 2007 | 82 | 2007 |
| Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure IAM MacPhee, S Spreafico, M Bewick, C Davis, JB Eastwood, A Johnston, ... Kidney international 57 (3), 1164-1168, 2000 | 76 | 2000 |
| A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype IAM MacPhee, DW Holt Transplantation 85 (2), 163-165, 2008 | 67 | 2008 |
| Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients CJ Kirwan, IAM MacPhee, T Lee, DW Holt, BJ Philips Intensive care medicine 38, 76-84, 2012 | 65 | 2012 |
| Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation R Bouamar, DA Hesselink, RHN van Schaik, W Weimar, IAM MacPhee, ... Therapeutic drug monitoring 33 (2), 178-184, 2011 | 65 | 2011 |
| Antigen-specific damage to brain vascular endothelial cells mediated by encephalitogenic and nonencephalitogenic CD4+ T cell lines in vitro. JD Sedgwick, CC Hughes, DK Male, IA MacPhee, V ter Meulen Journal of immunology (Baltimore, Md.: 1950) 145 (8), 2474-2481, 1990 | 65 | 1990 |
